PubRank

Robert F Siliciano

Author PubWeight™ 246.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003 9.75
2 Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013 6.47
3 Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012 6.29
4 Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006 5.41
5 The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002 4.73
6 Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006 4.62
7 Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2006 4.27
8 Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005 4.24
9 Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013 4.05
10 Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007 3.39
11 Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004 3.30
12 Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008 3.28
13 The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007 3.20
14 Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004 3.17
15 Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004 3.13
16 Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005 2.99
17 Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006 2.91
18 Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 2002 2.89
19 Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 2003 2.78
20 Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009 2.75
21 Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007 2.71
22 The multifactorial nature of HIV-1 latency. Trends Mol Med 2004 2.68
23 G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 2005 2.61
24 Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012 2.56
25 Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 2005 2.55
26 Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002 2.32
27 Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011 2.18
28 A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009 2.10
29 Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 2008 2.08
30 Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2006 2.08
31 Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006 2.06
32 Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013 2.02
33 Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis 2009 1.93
34 Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008 1.91
35 Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003 1.89
36 Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009 1.89
37 Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002 1.88
38 BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 2012 1.88
39 A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004 1.87
40 Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004 1.85
41 Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 2003 1.83
42 The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008 1.83
43 Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol 2008 1.82
44 Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog 2007 1.81
45 Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 2007 1.77
46 A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis 2008 1.76
47 Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 2015 1.76
48 Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A 2008 1.72
49 Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis 2010 1.70
50 A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 2012 1.68
51 Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 2010 1.66
52 Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol 2008 1.66
53 Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol 2004 1.64
54 The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS 2008 1.63
55 HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006 1.63
56 Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 2013 1.62
57 Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med 2012 1.61
58 The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008 1.50
59 Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog 2009 1.49
60 Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 2012 1.47
61 Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol 2007 1.47
62 Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 2007 1.47
63 A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 2013 1.46
64 No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010 1.45
65 HIV latency and integration site placement in five cell-based models. Retrovirology 2013 1.42
66 Can antiretroviral therapy ever be stopped? An update. AIDS Read 2004 1.42
67 Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. J Infect Dis 2007 1.41
68 Developing strategies for HIV-1 eradication. Trends Immunol 2012 1.38
69 Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004 1.34
70 Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol 2011 1.34
71 Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A 2011 1.33
72 A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol 2005 1.32
73 Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors. J Virol 2008 1.31
74 HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis 2012 1.29
75 Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol 2002 1.28
76 Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 2009 1.25
77 A novel PCR assay for quantification of HIV-1 RNA. J Virol 2013 1.25
78 Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Biol Chem 2010 1.24
79 Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 2008 1.22
80 Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc Natl Acad Sci U S A 2009 1.19
81 Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 2012 1.17
82 Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol 2006 1.16
83 HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS 2013 1.15
84 Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 2008 1.15
85 Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Antimicrob Chemother 2011 1.13
86 Preferential cytolysis of peripheral memory CD4+ T cells by in vitro X4-tropic human immunodeficiency virus type 1 infection before the completion of reverse transcription. J Virol 2008 1.12
87 A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci Transl Med 2011 1.11
88 A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci 2009 1.10
89 Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol 2010 1.10
90 Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. Retrovirology 2010 1.10
91 From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays 2013 1.07
92 Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem 2007 1.07
93 Barrier-to-autointegration factor BAF binds p55 Gag and matrix and is a host component of human immunodeficiency virus type 1 virions. J Virol 2003 1.06
94 CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc Natl Acad Sci U S A 2011 1.05
95 Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A 2013 1.04
96 The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. Curr Opin HIV AIDS 2006 1.04
97 New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis 2009 1.03
98 HIV-1-induced depletion of CD4+ T cells in the gut: mechanism and therapeutic implications. Trends Pharmacol Sci 2005 1.03
99 Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 2009 1.02
100 Treatment implications of the latent reservoir for HIV-1. Adv Pharmacol 2007 1.02
101 Keeping quiet: microRNAs in HIV-1 latency. Nat Med 2007 1.00
102 Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nat Commun 2012 0.99
103 Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Curr Opin Immunol 2004 0.97
104 Monitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution. J Virol 2008 0.97
105 Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells. Retrovirology 2013 0.96
106 Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology 2011 0.95
107 HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol 2014 0.94
108 Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J Immunol 2003 0.94
109 Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 2004 0.93
110 The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr Opin HIV AIDS 2006 0.93
111 Viral suppression of multiple escape mutants by de novo CD8(+) T cell responses in a human immunodeficiency virus-1 infected elite suppressor. Retrovirology 2011 0.92
112 Biomarkers of HIV replication. Curr Opin HIV AIDS 2010 0.91
113 HIV-1 evolution following transmission to an HLA-B*5801-positive patient. J Infect Dis 2009 0.91
114 Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses 2011 0.90
115 Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses. J Virol 2011 0.88
116 Recent trends in HIV-1 drug resistance. Curr Opin Virol 2013 0.88
117 Organization of cellular receptors into a nanoscale junction during HIV-1 adhesion. PLoS Comput Biol 2010 0.87
118 Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells. J Virol 2013 0.86
119 An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J Immunol 2004 0.86
120 Mycobacterium tuberculosis complex enhances susceptibility of CD4 T cells to HIV through a TLR2-mediated pathway. PLoS One 2012 0.86
121 Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemother 2013 0.85
122 Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. AIDS Res Hum Retroviruses 2013 0.85
123 Unraveling the relationship between microbial translocation and systemic immune activation in HIV infection. J Clin Invest 2014 0.85
124 Recent developments in the effort to cure HIV infection: going beyond N = 1. J Clin Invest 2016 0.85
125 Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. AIDS 2010 0.85
126 CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants. Retrovirology 2013 0.84
127 Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antivir Ther 2013 0.83
128 Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice. J Virol 2005 0.83
129 Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis 2010 0.83
130 A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides. J Antimicrob Chemother 2013 0.82
131 Elite suppression of HIV-1 replication. Immunity 2008 0.82
132 Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAART. HIV Clin Trials 2006 0.81
133 SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy. J Med Primatol 2005 0.81
134 Targeting HIV reservoirs with valproic acid. Hopkins HIV Rep 2005 0.81
135 Association of pol diversity with antiretroviral treatment outcomes among HIV-infected African children. PLoS One 2013 0.81
136 An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons. J Infect Dis 2002 0.81
137 Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. AIDS 2017 0.80
138 Crosscurrents in HIV-1 evolution. Nat Immunol 2006 0.79
139 A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potential. J Virol 2012 0.79
140 Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk. AIDS 2010 0.78
141 Achieving a quantitative understanding of antiretroviral drug efficacy. Clin Infect Dis 2010 0.78
142 Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients. JAMA 2002 0.77
143 Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins. Sci Rep 2013 0.77
144 The Effect of early treatment on the latent reservoir of HIV-1. J Infect Dis 2005 0.76
145 Immune alteration fends off AIDS. Nat Med 2008 0.76
146 Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro. AIDS 2015 0.75
147 Editorial: JQ1: giving HIV-1 expression a boost by blocking bromodomains? J Leukoc Biol 2012 0.75
148 Dual zinc-finger nucleases block HIV infection. Blood 2014 0.75
149 Corrigendum: Nuclear landscape of HIV-1 infection and integration. Nat Rev Microbiol 2017 0.75
150 Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. J Clin Invest 2017 0.75
151 A case of seronegative HIV-1 infection. J Infect Dis 2010 0.75
152 Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathog 2017 0.75